Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.49 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575920 | 1.00 | RAB9A (0.51) | RAB9ASMYD3PBKCHRNB2CHRNA7 | |
| SCHEMBL6084369 | 0.87 | KAT2B (0.56) | RAB9ACHRNB2CHRNA7CHRNA4CNR2 | |
| SCHEMBL6084376 | 0.87 | KAT2B (0.56) | RAB9ACHRNB2CHRNA7CHRNA4CNR2 | |
| SCHEMBL22449379 | 0.86 | HIF1A (0.56) | RAB9AACKR3 | |
| SCHEMBL19701301 | 0.85 | SMYD3 (0.61) | RAB9ASMYD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL23575894 | 0.85 | SMYD3 (0.61) | RAB9ASMYD3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3125620 | 0.80 | RAB9A (0.49) | RAB9ACHRNB2CHRNA7CHRNA4CNR2 | |
| SCHEMBL7391725 | 0.78 | ALDH1A1 (0.63) | CHRNB2CHRNA4 | |
| SCHEMBL14428750 | 0.77 | CHRNB2 (0.46) | RAB9ACHRNB2CHRNA7CHRNA4ACKR3 | |
| SCHEMBL21490080 | 0.77 | SMYD3 (0.51) | SMYD3PBKWNT1DYRK1AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | RAB9A 1388/4885SMYD3 1/4885PBK 4507/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | RAB9A 893/4885SMYD3 1/4885PBK 4705/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | RAB9A 890/4885SMYD3 1/4885PBK 4706/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | RAB9A 736/4885SMYD3 2/4885PBK 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.